Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q3 2023 · 10-Q
Revenue—
Net Income-$48.46M-$48.46MN/M vs Q3 2022 EPS Diluted-$0.73-$0.73N/M vs Q3 2022 Operating Income-$55,684,000N/M Operating Cash Flowderived-$48,079,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
Free Cash Flowderived-$49,279,000N/M ended Sep 30, 2023 · filed Nov 8, 2023 · 39 d after period end